| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD109 |
| Uniprot No | Q6YHK3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD109重组蛋白的3篇代表性文献的简要概述(注：以下内容为模拟示例，实际文献需通过学术数据库查询)：
1. **标题**：CD109 regulates TGF-β signaling via interaction with TGF-β receptor I
**作者**：S. Ito et al.
**摘要**：本研究通过重组表达CD109蛋白，揭示了其与TGF-β受体I的直接结合能力，证明CD109通过抑制Smad2/3磷酸化负调控TGF-β信号通路，影响细胞增殖和纤维化进程。
2. **标题**：Expression and functional characterization of recombinant CD109 in cancer progression
**作者**：A. Filopová et al.
**摘要**：作者利用哺乳动物表达系统制备了功能性CD109重组蛋白，发现其在多种肿瘤细胞中高表达，并通过激活STAT3通路促进肿瘤侵袭转移，提示其作为癌症治疗潜在靶点。
3. **标题**：Production of bioactive CD109 in HEK293 cells and its role in immune regulation
**作者**：J. Zhang et al.
**摘要**：该研究优化了CD109在HEK293细胞中的重组表达与纯化工艺，证实重组CD109可抑制巨噬细胞炎症因子释放，并通过调节TGF-β/IL-6交叉对话参与免疫稳态维持。
4. **标题**：Structural analysis of CD109 reveals GPI-anchored protein characteristics
**作者**：M. Suzuki et al.
**摘要**：通过重组CD109的晶体结构解析，发现其C端GPI锚定结构域对细胞膜定位至关重要，并揭示了其与血小板衍生生长因子受体(PDGFR)的相互作用机制，为相关疾病机制研究提供结构基础。
**Background on CD109 Recombinant Protein**
CD109. a glycosylphosphatidylinositol (GPI)-anchored cell surface protein, belongs to the TGF-β receptor superfamily. It plays a critical role in regulating transforming growth factor-beta (TGF-β) signaling, a pathway central to cell proliferation, differentiation, and immune responses. Structurally, CD109 contains leucine-rich repeats and a GPI anchor, facilitating its interaction with extracellular ligands and membrane-associated signaling complexes.
Functionally, CD109 acts as a co-receptor that modulates TGF-β1 signaling by sequestering the cytokine or competing with type I receptors, thereby attenuating Smad2/3 activation. This regulatory mechanism impacts processes like wound healing, angiogenesis, and immune regulation. CD109 is expressed on activated T cells, platelets, endothelial cells, and certain stem cells, including mesenchymal and cancer stem cells, linking it to tissue homeostasis and disease progression.
Dysregulation of CD109 is implicated in pathologies such as cancer, fibrosis, and inflammatory disorders. In tumors, elevated CD109 levels correlate with poor prognosis, metastasis, and resistance to therapy, likely through promoting epithelial-mesenchymal transition (EMT) and angiogenesis. Conversely, CD109 loss exacerbates fibrosis by enhancing TGF-β-driven collagen deposition.
Recombinant CD109 protein, typically produced in mammalian expression systems to preserve post-translational modifications, serves as a vital tool for studying TGF-β signaling dynamics, receptor interactions, and therapeutic targeting. It enables in vitro assays, antibody development, and exploration of CD109-based biologics to treat conditions like cancer or fibrotic diseases. Research on recombinant CD109 continues to unravel its dual role as both a biomarker and a modulator of critical cellular pathways, highlighting its potential in translational medicine.
(Word count: 247)
×
